Tag Archives: Celgene

FiercePharmaAsia—Japan’s global first nods; Celgene hands back PD-1; China’s copycat invite

Japan’s health ministry has sent out global first nods to drugs from Roche, Daiichi Sankyo and AstraZeneca. Two years after penning the licensing deal, Celgene has returned PD-1 tislelizumab to BeiGene along with a $ 150 million breakup fee. Multinational biopharma companies’ older medicines in China are under threat as authorities have made a list of 34… Read More »

Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed. In a Friday proxy filing, the company said it had drafted former Celgene CEO and M&A engineer Bob Hugin to head up a new deal-focused committee. Three current board members will round out the panel,… Read More »

Does Bristol-Myers Squibb’s new activist investor want to stall its Celgene buyout?

Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $ 74 billion Celgene deal agreement. And an activist may be joining that list. Known agitator Starboard Value has taken a stake in the New Jersey drugmaker, Bloomberg’s sources say, though the size of that stake and the hedge fund’s plans are still unclear. A… Read More »